Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Champions Oncology (CSBR) Stock Forecast & Price Target

Champions Oncology logo
Get the Latest News and Ratings for CSBR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Champions Oncology and its competitors.

Sign Up

CSBR Analyst Ratings Over Time

TypeCurrent Forecast
11/9/23 to 11/8/24
1 Month Ago
10/10/23 to 10/9/24
3 Months Ago
8/11/23 to 8/10/24
1 Year Ago
11/9/22 to 11/9/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.00$6.00$7.50$9.75
Forecasted Upside36.67% Upside28.76% Upside68.16% Upside77.60% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

CSBR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSBR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Champions Oncology Stock vs. The Competition

TypeChampions OncologyMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside38.89% Upside10,007.57% Upside7.56% Upside
News Sentiment Rating
Positive News

See Recent CSBR News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/12/2024Craig Hallum
3 of 5 stars
M. Hewitt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$6.00 ➝ $6.00+49.63%
9/22/2023Roth Mkm
1 of 5 stars
 Lower TargetBuy ➝ Buy$9.00 ➝ $7.50+40.71%
3/16/2023Benchmark
2 of 5 stars
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:57 PM ET.


CSBR Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Champions Oncology is $6.00, with a high forecast of $6.00 and a low forecast of $6.00.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CSBR shares.

According to analysts, Champions Oncology's stock has a predicted upside of 36.67% based on their 12-month stock forecasts.

Over the previous 90 days, Champions Oncology's stock had 1 upgrade by analysts.

Champions Oncology has been rated by research analysts at Craig Hallum in the past 90 days.

Analysts like Champions Oncology more than other "medical" companies. The consensus rating for Champions Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CSBR compares to other companies.


This page (NASDAQ:CSBR) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners